AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37258077 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of aerobic exercise
Number of subjects: 80
Study 37258077 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 80
Study 37258079 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seropositivity testing
Number of subjects: 332
Study 37258079 — intervention group
Group type: EXPERIMENTAL
Intervention: Household factors (type 2 diabetes, food stamps, lower education)
Number of subjects: 332
Study 37258080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 220
Study 37258080 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 220
Study 37258095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose combination (FDC) of two or more antihypertensives and a statin with or without aspirin
Number of subjects: 18162
Study 37258095 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC with aspirin
Number of subjects: 18162
Study 37258095 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC without aspirin
Number of subjects: 18162
Study 37258095 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18162
Study 37258095 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC
Number of subjects: 18162
Study 37258095 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 18162
Study 37258299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-Disordered Breathing (SDB) severity
Number of subjects: 122
Study 37258299 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea-hypopnea index
Number of subjects: 122
Study 37258525 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome Enhancer Diet (MBD)
Number of subjects: 0
Study 37258525 — intervention group
Group type: COMPARATOR
Intervention: Western Diet (WD)
Number of subjects: 0
Study 37258647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mucosal biopsy and sinonasal examination
Number of subjects: 40
Study 37258647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinonasal outcome test-22 (SNOT-22)
Number of subjects: 40
Study 37258647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough evaluation test (CET)
Number of subjects: 40
Study 37258647 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SNOT-22 and CET
Number of subjects: 40
Study 37258715 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (100 mg) and LSD (100 µg)
Number of subjects: 24
Study 37258715 — intervention group
Group type: COMPARATOR
Intervention: LSD alone
Number of subjects: 24
Study 37258715 — intervention group
Group type: COMPARATOR
Intervention: MDMA alone
Number of subjects: 24
Study 37258715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 37259053 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM) treatment for 6 months
Number of subjects: 396
Study 37259081 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) to adopt Team-Based Care (TBC) principles for hypertension management
Number of subjects: 90
Study 37259081 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF)
Number of subjects: 90
Study 37259081 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 90
Study 37259087 — intervention group
Group type: EXPERIMENTAL
Intervention: myPlan app (n=147)
Number of subjects: 293
Study 37259087 — intervention group
Group type: COMPARATOR
Intervention: Control (usual web-based resources; n=146)
Number of subjects: 293
Study 37259124 — intervention group
Group type: COMPARATOR
Intervention: ParkinsonAKTIV intervention (online platform for guiding non-pharmacological treatment decisions)
Number of subjects: 0
Study 37259124 — intervention group
Group type: COMPARATOR
Intervention: Health-related quality of life and physician-assessed health status (Unified Parkinson Disease Rating Scale)
Number of subjects: 0
Study 37259124 — intervention group
Group type: COMPARATOR
Intervention: Health economic evaluation using patient-reported outcomes and cost data
Number of subjects: 0
Study 37259138 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 13
Study 37259147 — intervention group
Group type: COMPARATOR
Intervention: University-based comprehensive stroke centres (UCSC)
Number of subjects: 3431
Study 37259147 — intervention group
Group type: COMPARATOR
Intervention: Non university-based comprehensive stroke centres (nUCSC)
Number of subjects: 3431
Study 37259147 — intervention group
Group type: COMPARATOR
Intervention: Primary stroke centres at non-university hospitals (PCS)
Number of subjects: 3431
Study 37259147 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe stroke (NIHSS score ≥5)
Number of subjects: 3431
Study 37259147 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ischaemic stroke vs. TIA
Number of subjects: 3431
Study 37259147 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients younger than 60 years
Number of subjects: 3431
Study 37259147 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography (TTE and/or TEE)
Number of subjects: 3431
Study 37259147 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of AF in-hospital
Number of subjects: 3431
Study 37259157 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia plus usual care
Number of subjects: 135
Study 37259157 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 135
Study 37259190 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive step training (2 weeks, 6 sessions)
Number of subjects: 25
Study 37259248 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of ketone ester (KE)
Number of subjects: 10
Study 37259248 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (EX CON)
Number of subjects: 10
Study 37259248 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (R CON)
Number of subjects: 10
Study 37259253 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR group (traditional rehabilitation with a medical grade tourniquet applied to the upper arm)
Number of subjects: 28
Study 37259253 — intervention group
Group type: COMPARATOR
Intervention: Non-BFR group (traditional rehabilitation only)
Number of subjects: 28
Study 37259255 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (150 min of supervised, moderate-intensity aerobic exercise per week for 24 weeks)
Number of subjects: 0
Study 37259255 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 37259255 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exercise attendance
Number of subjects: 0
Study 37259255 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exercise level
Number of subjects: 0
Study 37259255 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exercise level and infant activity state
Number of subjects: 0
Study 37259323 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine treatment
Number of subjects: 49
Study 37259500 — intervention group
Group type: EXPERIMENTAL
Intervention: Female AIS patients
Number of subjects: 482
Study 37259500 — intervention group
Group type: COMPARATOR
Intervention: Male AIS patients
Number of subjects: 482
Study 37259567 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (75 mg/m2 days 1-7) + Lenalidomide (2.5 or 5 mg days 1-21) + Donor lymphocyte infusions (0.5×10^6-1.5×10^7 cells/kg)
Number of subjects: 50
Study 37259567 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine + Lenalidomide + Donor lymphocyte infusions
Number of subjects: 50
Study 37259592 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental occupational therapy plus intensive standard rehabilitation
Number of subjects: 92
Study 37259605 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated Albumin (GA)
Number of subjects: 34
Study 37259605 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated Hemoglobin A1c (HbA1c)
Number of subjects: 34
Study 37259693 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5% solution, administered as two drops to the most affected eye.
Number of subjects: 10
Study 37259789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Channeling
Number of subjects: 0
Study 37259789 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37259807 — intervention group
Group type: EXPERIMENTAL
Intervention: circSCORE
Number of subjects: 149
Study 37259807 — intervention group
Group type: COMPARATOR
Intervention: MCL35
Number of subjects: 149
Study 37259859 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic total occlusion percutaneous coronary intervention (CTO PCI)
Number of subjects: 12928
Study 37259861 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 369
Study 37259861 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 369
Study 37260074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF
Number of subjects: 1914
Study 37260130 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (onabotA)
Number of subjects: 504
Study 37260158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg orally twice daily (BID)
Number of subjects: 136
Study 37260158 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally BID
Number of subjects: 136
Study 37260158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg orally BID
Number of subjects: 136
Study 37260160 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocare (VR solution)
Number of subjects: 102
Study 37260160 — intervention group
Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 102
Study 37260252 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 318
Study 37260254 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional boost with ALVAC-HIV and AIDSVAX (group 2)
Number of subjects: 0
Study 37260254 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional boost with AIDSVAX alone (group 3)
Number of subjects: 0
Study 37260254 — intervention group
Group type: COMPARATOR
Intervention: No additional boost (group 1)
Number of subjects: 0
Study 37260254 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional boost
Number of subjects: 0
Study 37260254 — intervention group
Group type: EXPERIMENTAL
Intervention: Trogocytosis
Number of subjects: 0
Study 37260312 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical interval (from first consultation to appropriate antibiotics administration)
Number of subjects: 227
Study 37260312 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient interval (from first signs of COSBI to the first medical consultation)
Number of subjects: 227
Study 37260312 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial hospital referral for consultation
Number of subjects: 227
Study 37260368 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI)
Number of subjects: 307
Study 37261117 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer/LDH/leukocytes
Number of subjects: 93
Study 37261117 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer/LDH/neutrophils
Number of subjects: 93
Study 37261117 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer/LDH/leukocytes/neutrophils
Number of subjects: 93
Study 37261117 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory data (leukocytes, neutrophils, D-dimer, LDH)
Number of subjects: 93
Study 37261117 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2 protein
Number of subjects: 93
Study 37261117 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte inhibitory factor
Number of subjects: 93
Study 37261364 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 2dd300 mg
Number of subjects: 20
Study 37261384 — intervention group
Group type: EXPERIMENTAL
Intervention: MINOCA females ≤70 years old
Number of subjects: 2455
Study 37261384 — intervention group
Group type: COMPARATOR
Intervention: MINOCA males
Number of subjects: 2455
Study 37261384 — intervention group
Group type: COMPARATOR
Intervention: MIOCA females
Number of subjects: 2455
Study 37261384 — intervention group
Group type: COMPARATOR
Intervention: MIOCA males
Number of subjects: 2455
Study 37261531 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant 25 mg
Number of subjects: 310
Study 37261531 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant 75 mg
Number of subjects: 310
Study 37261531 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant 150 mg
Number of subjects: 310
Study 37261531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 37261566 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation and navigation program including EHR decision support tool, consultation with a child and adolescent psychiatrist, and up to 6 months of behavioral health care navigation
Number of subjects: 348
Study 37261615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-18-labeled SSAs
Number of subjects: 10
Study 37261615 — intervention group
Group type: COMPARATOR
Intervention: Gallium-68-labeled SSAs
Number of subjects: 10
Study 37261636 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PoTS
Number of subjects: 30
Study 37261636 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 30
Study 37261654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (AET)
Number of subjects: 309
Study 37261654 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent pain interference
Number of subjects: 309
Study 37261654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor receipt
Number of subjects: 309
Study 37261654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 309
Study 37261654 — intervention group
Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 309
Study 37261654 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent endocrine symptoms
Number of subjects: 309
Study 37261654 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stage
Number of subjects: 309
Study 37261654 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent physical function decline
Number of subjects: 309
Study 37261664 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate 2-6 mg plus spironolactone 100-200 mg
Number of subjects: 19
Study 37261664 — intervention group
Group type: COMPARATOR
Intervention: PrEP (tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg)
Number of subjects: 19
Study 37261804 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg IV every 2 weeks), Apatinib (250 mg oral once daily), Temozolomide (200 mg/m2 IV once daily on days 1-5)
Number of subjects: 50
Study 37261806 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy (ART)
Number of subjects: 132
Study 37261806 — intervention group
Group type: COMPARATOR
Intervention: Standard Intensity-Modulated Radiotherapy (IMRT)
Number of subjects: 132
Study 37261806 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 132
Study 37261831 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (fluorouracil or capecitabine, with some receiving doublet chemotherapy or bevacizumab)
Number of subjects: 24
Study 37261831 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 24
Study 37261831 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 24
Study 37261831 — intervention group
Group type: COMPARATOR
Intervention: Observation-first group
Number of subjects: 24
Study 37261831 — intervention group
Group type: COMPARATOR
Intervention: Treatment-first group
Number of subjects: 24
Study 37261839 — intervention group
Group type: COMPARATOR
Intervention: Low-dose atropine 0.02%
Number of subjects: 576
Study 37261839 — intervention group
Group type: COMPARATOR
Intervention: Low-dose atropine 0.01%
Number of subjects: 576
Study 37261839 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 576
Study 37261885 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth lifestyle intervention (details not specified)
Number of subjects: 14
Study 37261907 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI)
Number of subjects: 37
Study 37261907 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (IVMP)
Number of subjects: 37
Study 37261916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 765
Study 37261916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 765
Study 37261916 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline electroretinogram 30-Hz flicker implicit time
Number of subjects: 765
Study 37261916 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic subtype
Number of subjects: 765
Study 37262038 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured nutrition and advanced carbohydrate counting questionnaire
Number of subjects: 0
Study 37262040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) administered as part of triple-drug therapy, with dosing groups of 200 μg/kg, 18 mg, and 36 mg.
Number of subjects: 56
Study 37262040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) administered as part of triple-drug therapy.
Number of subjects: 56
Study 37262066 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2 monitoring using TCM4
Number of subjects: 100
Study 37262066 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2 monitoring using TCM5
Number of subjects: 100
Study 37262066 — intervention group
Group type: COMPARATOR
Intervention: Arterial blood gas (ABG) measurements
Number of subjects: 100
Study 37262130 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and attitudes toward hospice and palliative care
Number of subjects: 35
Study 37262189 — intervention group
Group type: EXPERIMENTAL
Intervention: Parboiled ribe rice
Number of subjects: 10
Study 37262189 — intervention group
Group type: EXPERIMENTAL
Intervention: Parboiled long B rice (flora method)
Number of subjects: 10
Study 37262189 — intervention group
Group type: EXPERIMENTAL
Intervention: Parboiled long B rice (conventional method)
Number of subjects: 10
Study 37262189 — intervention group
Group type: EXPERIMENTAL
Intervention: White rice cake (by-product of parboiled rice)
Number of subjects: 10
Study 37262189 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown rice cake (by-product of parboiled rice)
Number of subjects: 10
Study 37262189 — intervention group
Group type: EXPERIMENTAL
Intervention: Different varieties of parboiled rice (ribe, white and brown long B, basmati, black, red, roma, and arborio)
Number of subjects: 10
Study 37262194 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37262929 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meals
Number of subjects: 0
Study 37262929 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate meals
Number of subjects: 0
Study 37262929 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva insulin
Number of subjects: 0
Study 37262961 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rucaparib (600 mg twice daily)
Number of subjects: 0
Study 37262961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37262961 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rucaparib
Number of subjects: 0
Study 37263066 — intervention group
Group type: COMPARATOR
Intervention: 120 %BW (20 % increased bodyweight)
Number of subjects: 10
Study 37263066 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 10
Study 37263066 — intervention group
Group type: COMPARATOR
Intervention: 120 %BW
Number of subjects: 10
Study 37263121 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening questionnaire
Number of subjects: 1191
Study 37263121 — intervention group
Group type: EXPERIMENTAL
Intervention: CTEPH incidence
Number of subjects: 1191
Study 37263121 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-step triage algorithm
Number of subjects: 1191
Study 37263361 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL) without resection combined with single-incision needle-knife (SINK) biopsy sampling
Number of subjects: 122
Study 37263380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 1059
Study 37263523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin (n = 43)
Number of subjects: 86
Study 37263523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 43)
Number of subjects: 86
Study 37263649 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GOL)
Number of subjects: 530
Study 37263673 — intervention group
Group type: EXPERIMENTAL
Intervention: KN046 administered at doses of 1, 3, and 5 mg/kg every 2 weeks (Q2W), 5 mg/kg every 3 weeks (Q3W), and 300 mg Q3W.
Number of subjects: 100
Study 37263673 — intervention group
Group type: EXPERIMENTAL
Intervention: KN046
Number of subjects: 100
Study 37263673 — intervention group
Group type: EXPERIMENTAL
Intervention: KN046 in NPC subgroup
Number of subjects: 100
Study 37263673 — intervention group
Group type: EXPERIMENTAL
Intervention: KN046 in EGFR-mutant NSCLC subgroup
Number of subjects: 100
Study 37263683 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral antibiotics
Number of subjects: 0
Study 37263683 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 0
Study 37263684 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based falls prevention programme with group-based strength and balance exercises
Number of subjects: 60
Study 37263684 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 60
Study 37263708 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care programme (DWM and PM+)
Number of subjects: 232
Study 37263708 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care as usual (eCAU)
Number of subjects: 232
Study 37263896 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 733
Study 37263896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study 37263914 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed nuts (42.5 g/day)
Number of subjects: 29